Researchers at the Israel Institute for Biological Research (IIBR) say that a combination of two existing antiviral drugs appear to inhibit the growth of SARS CoV-2.

Medial EarlySign's machine learning-based solutions are being harnessed by Maccabi to flag patients who are likely to develop related illnesses during this particularly harsh flu season.

The National Institutes of Health announced a new Phase 2 clinical trial of the M-001 vaccine candidate, developed and produced by BiondVax Pharmaceuticals.

Flu vaccinations ahead of the winter have become popular, but they do not protect against the potentially deadly bird flu, which mutates frequently and grows resistant to treatment. Israeli company BiondVax has developed a universal vaccine that could eradicate the flu.